Research
Hormonal
Bariatric surgery induces rapid hormonal changes (increased GLP-1, PYY, decreased ghrelin) and bile acid signaling that drive early satiety and metabolic improvements, independent of caloric restriction.
Bariatric surgery works by changing your body's hormones, not just by making your stomach smaller. You will likely feel full faster and have less hunger due to increased GLP-1 and PYY and decreased ghrelin. This biological shift supports your ability to stick to dietary changes.
GoodSupportsHIGH confidence
The biological basis of EWL is multifactorial, involving anatomical restriction, hormonal adaptations, and changes in bile acid metabolism and the gut microbiome.
Why this rating
Supported by multiple physiological studies cited in the review.
Source
Clinical Significance of Early Postoperative Weight Loss in Bariatric Surgery: A Narrative Review
Su Mi Kim · Journal of Metabolic and Bariatric Surgery · 2025
DOI 10.17476/jmbs.2025.14.2.139
narrative_reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Achieving ≥20–25% early postoperative weight loss (EWL) within the first 3–6 months after bariatric surgery strongly predicts sustained long-term weight loss (≥50% EWL) and metabolic remission.Good
- Early slow responders to bariatric surgery (low EWL at 3 months) should be identified through routine monitoring and offered intensified interventions, including pharmacologic support like GLP-1 receptor agonists.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →